Agent Capital related stories
All articles and analysis
Palvella Therapeutics rakes in $45m Series CWayne, Pennsylvania-based Palvella Therapeutics Inc., a rare disease biopharmaceutical company, has raised $45 million in Series C financing.
VC-backed Entrada Therapeutics hires COOBoston-based Entrada Therapeutics, a biotechnology company, has appointed Nathan J. Dowden as chief operating officer. Recently, he worked at Rubius Therapeutics where he was senior vice president of strategy and corporate development. Entrada's backers include 5AM Ventures, MPM Capital, Roche Venture Fund, MRL Ventures Fund and Agent Capital.
- Pyxis Oncology rakes in $22 mln Series A
Boston-based Pyxis Oncology, a newly formed immuno-oncology company, has raised $22 million in Series A funding. Leaps by Bayer led the round with participation from other investors that included Agent Capital, Ipsen and Longwood Fund.
- Entrada Therapeutics scores $59 mln Series A
Boston-based Entrada Therapeutics, a biotechnology company, has raised $59 million in Series A financing. The lead investors were 5AM Ventures and MPM Capital. Other participants in the round were Roche Venture Fund, MRL Ventures Fund and Agent Capital.
- Pliant Therapeutics snags $62 mln Series B
South San Francisco-based Pliant Therapeutics Inc, a biotech firm, has raised $62 million in Series B financing. Cowen Healthcare Investments led the round with participation from other investors that included Eventide Asset Management, Schroder Adveq, Menlo Ventures, SCubed Capital and Agent Capital.
- Verge Genomics raises $32 mln from DFJ, ALS Investment Fund, Agent Capital, others
Verge Genomics said it raised $32 million of Series A capital in a round led by DFJ and joined by new investors WuXi AppTec’s Corporate Venture Fund, ALS Investment Fund, Agent Capital, and OS Fund.